Philips Launches Occlusion Balloon Capable of Reducing Blood Loss by 90%
Royal Philips announces the launch of the Bridge Plus Occlusion Balloon, a next-generation balloon designed for electrophysiology teams. This device quickly controls bleeding during superior vena cava tears in transvenous lead extraction procedures.
Efficient Hemostasis and Rapid Deployment
The Bridge Plus is engineered to ensure temporary vessel occlusion, reduce bleeding, and maintain hemostasis during emergencies. According to the press release, the balloon deploys in less than two minutes, reduces blood loss by up to 90%, and maintains acceptable hemostasis for at least 30 minutes. This technology is based on a platform proven in over 50,000 procedures. The device is equipped with radiopaque markers for precise positioning and adapts to a wide range of patient anatomies.
Availability and Upcoming Presentation
The Bridge Plus Occlusion Balloon is now available in the United States. International availability is expected later in 2026, subject to national regulatory approvals. The device will be featured at the Heart Rhythm Society congress 2026, which will be held from April 24 to 26 in Chicago. This initiative expands Philips' portfolio of lead management solutions dedicated to safe and effective extraction procedures.
